Literature DB >> 22883936

The risk of paradoxical embolism (RoPE) study: initial description of the completed database.

David E Thaler1, Emanuele Di Angelantonio, Marco R Di Tullio, Jennifer S Donovan, John Griffith, Shunichi Homma, Cheryl Jaigobin, Jean-Louis Mas, Heinrich P Mattle, Patrik Michel, Marie-Luise Mono, Krassen Nedeltchev, Federica Papetti, Robin Ruthazer, Joaquín Serena, Christian Weimar, Mitchell S V Elkind, David M Kent.   

Abstract

BACKGROUND: Detecting a benefit from closure of patent foramen ovale in patients with cryptogenic stroke is hampered by low rates of stroke recurrence and uncertainty about the causal role of patent foramen ovale in the index event. A method to predict patent foramen ovale-attributable recurrence risk is needed. However, individual databases generally have too few stroke recurrences to support risk modeling. Prior studies of this population have been limited by low statistical power for examining factors related to recurrence. AIMS: The aim of this study was to develop a database to support modeling of patent foramen ovale-attributable recurrence risk by combining extant data sets.
METHODS: We identified investigators with extant databases including subjects with cryptogenic stroke investigated for patent foramen ovale, determined the availability and characteristics of data in each database, collaboratively specified the variables to be included in the Risk of Paradoxical Embolism database, harmonized the variables across databases, and collected new primary data when necessary and feasible.
RESULTS: The Risk of Paradoxical Embolism database has individual clinical, radiologic, and echocardiographic data from 12 component databases, including subjects with cryptogenic stroke both with (n = 1925) and without (n = 1749) patent foramen ovale. In the patent foramen ovale subjects, a total of 381 outcomes (stroke, transient ischemic attack, death) occurred (median follow-up 2·2 years). While there were substantial variations in data collection between studies, there was sufficient overlap to define a common set of variables suitable for risk modeling.
CONCLUSION: While individual studies are inadequate for modeling patent foramen ovale-attributable recurrence risk, collaboration between investigators has yielded a database with sufficient power to identify those patients at highest risk for a patent foramen ovale-related stroke recurrence who may have the greatest potential benefit from patent foramen ovale closure.
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization.

Entities:  

Keywords:  cryptogenic stroke; endovascular closure; individual patient meta-analysis; patent foramen ovale; risk modeling; secondary stroke prevention

Mesh:

Year:  2012        PMID: 22883936      PMCID: PMC4060865          DOI: 10.1111/j.1747-4949.2012.00843.x

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  25 in total

1.  Structural and compliant anatomy of the patent foramen ovale in patients undergoing transcatheter closure.

Authors:  A C Marshall; J E Lock
Journal:  Am Heart J       Date:  2000-08       Impact factor: 4.749

Review 2.  Is patent foramen ovale a modifiable risk factor for stroke recurrence?

Authors:  David M Kent; David E Thaler
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

3.  Recurrent stroke on imaging and presumed paradoxical embolism: a cross-sectional analysis.

Authors:  Georgios D Kitsios; Aaron Lasker; Jasmeet Singh; David E Thaler
Journal:  Neurology       Date:  2012-03-14       Impact factor: 9.910

4.  Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke.

Authors:  M M Steiner; M R Di Tullio; T Rundek; R Gan; X Chen; C Liguori; M Brainin; S Homma; R L Sacco
Journal:  Stroke       Date:  1998-05       Impact factor: 7.914

5.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.

Authors:  J L Mas; C Arquizan; C Lamy; M Zuber; L Cabanes; G Derumeaux; J Coste
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

6.  Recurrent stroke/TIA in cryptogenic stroke patients with patent foramen ovale.

Authors:  Leanne Casaubon; Peter McLaughlin; Gary Webb; Erik Yeo; Darren Merker; Cheryl Jaigobin
Journal:  Can J Neurol Sci       Date:  2007-02       Impact factor: 2.104

7.  Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study.

Authors:  Joaquín Serena; Joan Marti-Fàbregas; Estevo Santamarina; Juan Jesús Rodríguez; María Jesús Perez-Ayuso; Jaime Masjuan; Tomás Segura; Jaime Gállego; Antonio Dávalos
Journal:  Stroke       Date:  2008-09-25       Impact factor: 7.914

Review 8.  Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.

Authors:  J Donald Easton; Jeffrey L Saver; Gregory W Albers; Mark J Alberts; Seemant Chaturvedi; Edward Feldmann; Thomas S Hatsukami; Randall T Higashida; S Claiborne Johnston; Chelsea S Kidwell; Helmi L Lutsep; Elaine Miller; Ralph L Sacco
Journal:  Stroke       Date:  2009-05-07       Impact factor: 7.914

9.  Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study.

Authors:  Marco R Di Tullio; Shunichi Homma; Zhezhen Jin; Ralph L Sacco
Journal:  J Am Coll Cardiol       Date:  2008-09-02       Impact factor: 24.094

10.  The Risk of Paradoxical Embolism (RoPE) Study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke.

Authors:  David M Kent; David E Thaler
Journal:  Trials       Date:  2011-07-27       Impact factor: 2.279

View more
  13 in total

1.  Patent foramen ovale closure for patients excluded from the randomized cryptogenic stroke trials.

Authors:  Muhammad O Zaman; Nimesh K Patel; Mohammad K Mojadidi
Journal:  Clin Res Cardiol       Date:  2018-06-28       Impact factor: 5.460

2.  Response to letter regarding article, "Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale analysis of putative high-risk features from the risk of paradoxical embolism database".

Authors:  Benjamin S Wessler; David E Thaler; Robin Ruthazer; Christian Weimar; Marco R Di Tullio; Mitchell S V Elkind; Shunichi Homma; Jennifer S Lutz; Jean-Louis Mas; Heinrich P Mattle; Bernhard Meier; Krassen Nedeltchev; Federica Papetti; Emanuele Di Angelantonio; Mark Reisman; Joaquín Serena; David M Kent
Journal:  Circ Cardiovasc Imaging       Date:  2014-05       Impact factor: 7.792

Review 3.  Role of PFO Closure in Ischemic Stroke Prevention.

Authors:  Nicholas D Osteraas; Alejandro Vargas; Laurel Cherian; Sarah Song
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-14

4.  Neuroimaging findings in cryptogenic stroke patients with and without patent foramen ovale.

Authors:  David E Thaler; Robin Ruthazer; Emanuele Di Angelantonio; Marco R Di Tullio; Jennifer S Donovan; Mitchell S V Elkind; John Griffith; Shunichi Homma; Cheryl Jaigobin; Jean-Louis Mas; Heinrich P Mattle; Patrik Michel; Marie-Luise Mono; Krassen Nedeltchev; Federica Papetti; Joaquín Serena; Christian Weimar; David M Kent
Journal:  Stroke       Date:  2013-01-22       Impact factor: 7.914

Review 5.  Cryptogenic stroke: how to define it? How to treat it?

Authors:  Ava L Liberman; Shyam Prabhakaran
Journal:  Curr Cardiol Rep       Date:  2013-12       Impact factor: 2.931

Review 6.  Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis.

Authors:  David M Kent; Issa J Dahabreh; Robin Ruthazer; Anthony J Furlan; Christian Weimar; Joaquín Serena; Bernhard Meier; Heinrich P Mattle; Emanuele Di Angelantonio; Maurizio Paciaroni; Herwig Schuchlenz; Shunichi Homma; Jennifer S Lutz; David E Thaler
Journal:  Eur Heart J       Date:  2015-07-03       Impact factor: 29.983

7.  Clinical RoPE (cRoPE) score predicts patent foramen ovale detection among stroke patients: a multicenter observational study.

Authors:  David Giannandrea; Michele Romoli; Chiara Padiglioni; Paolo Eusebi; Anna Mengoni; Franco Galati; Antonio Vecchio; Silvia Cenciarelli; Stefano Ricci; Domenico Consoli
Journal:  Neurol Sci       Date:  2020-05-09       Impact factor: 3.307

8.  Determinants of antithrombotic choice for patent foramen ovale in cryptogenic stroke.

Authors:  David E Thaler; Robin Ruthazer; Christian Weimar; Joaquín Serena; Heinrich P Mattle; Krassen Nedeltchev; Marie-Luise Mono; Emanuele Di Angelantonio; Mitchell S V Elkind; Marco R Di Tullio; Shunichi Homma; Patrik Michel; Bernhard Meier; Anthony J Furlan; Jennifer S Lutz; David M Kent
Journal:  Neurology       Date:  2014-10-22       Impact factor: 9.910

9.  Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database.

Authors:  Benjamin S Wessler; David E Thaler; Robin Ruthazer; Christian Weimar; Marco R Di Tullio; Mitchell S V Elkind; Shunichi Homma; Jennifer S Lutz; Jean-Louis Mas; Heinrich P Mattle; Bernhard Meier; Krassen Nedeltchev; Federica Papetti; Emanuele Di Angelantonio; Mark Reisman; Joaquín Serena; David M Kent
Journal:  Circ Cardiovasc Imaging       Date:  2013-11-08       Impact factor: 7.792

10.  An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke.

Authors:  David M Kent; Robin Ruthazer; Christian Weimar; Jean-Louis Mas; Joaquín Serena; Shunichi Homma; Emanuele Di Angelantonio; Marco R Di Tullio; Jennifer S Lutz; Mitchell S V Elkind; John Griffith; Cheryl Jaigobin; Heinrich P Mattle; Patrik Michel; Marie-Louise Mono; Krassen Nedeltchev; Federica Papetti; David E Thaler
Journal:  Neurology       Date:  2013-07-17       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.